Case 1993.

Methods	randomized controlled trial, placebo‐controlled
Participants	n = 157, hematological malignancies, breast, lung, gynecological, gastrointestinal, other cancer; concomitant treatment: chemotherapy
Interventions	drug = Epoetin alpha dose = 150 IU/kg sc TIW hb‐target = Hct 38%‐40% planned ESA duration = 12 weeks
Outcomes	Transfusion, Hct, QoL, safety
Notes	study number = 34917
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Low risk	computer‐generated
Allocation concealment?	Unclear risk	description is unclear